1981
High-volume intraperitoneal chemotherapy with methotrexate in patients with cancer.
Jones R, Collins J, Myers C, Brooks A, Hubbard S, Balow J, Brennan M, Dedrick R, DeVita V. High-volume intraperitoneal chemotherapy with methotrexate in patients with cancer. Cancer Research 1981, 41: 55-9. PMID: 7448776.Peer-Reviewed Original ResearchConceptsEpisodes of bacterial peritonitisNovel treatment modalitiesTotal body clearanceIntraperitoneal chemotherapyPeritoneal irritationChemotherapeutic regimensMethotrexate clearanceBacterial peritonitisOvarian cancerMalignant melanomaTreatment modalitiesLocal toxicitySystemic toxicityPlasma levelsPeritoneal cavitySystemic circulationTreatment cyclesPlasma concentrationsMethotrexate concentrationsTherapeutic benefitBody clearancePatientsMethotrexateChemotherapyPeritonitis
1980
Phase I and pharmacological studies of 5-fluorouracil administered intraperitoneally.
Speyer J, Collins J, Dedrick R, Brennan M, Buckpitt A, Londer H, DeVita V, Myers C. Phase I and pharmacological studies of 5-fluorouracil administered intraperitoneally. Cancer Research 1980, 40: 567-72. PMID: 7471076.Peer-Reviewed Original ResearchConceptsPeritoneal fluid concentrationsPlasma levelsGram-negative bacterial peritonitisTenckhoff peritoneal dialysis catheterCentral nervous system toxicityStudy of 5-fluorouracilDose-limiting toxicityPeritoneal fluid levelsSimultaneously measured plasma levelsPhase I studyPeritoneal dialysis catheterNervous system toxicityMild abdominal discomfortRoute of administrationTotal body clearanceFluid concentrationsPattern of toxicityBacterial peritonitisDialysis catheterAbdominal discomfortSystemic toxicityPharmacological advantagesDialysate concentrationsBody clearanceFluid levels
1979
Treatment of refractory splenomegaly in myeloproliferative disease by splenic artery infusion.
Canellos G, Sutliffe S, DeVita V, Lister T. Treatment of refractory splenomegaly in myeloproliferative disease by splenic artery infusion. Blood 1979, 53: 1014-7. PMID: 435637, DOI: 10.1182/blood.v53.5.1014.bloodjournal5351014.Peer-Reviewed Original ResearchConceptsSplenic artery infusionArterial infusionBlastic phase of chronic granulocytic leukemiaRefractory to previous therapyPhase of chronic granulocytic leukemiaChronic granulocytic leukemiaResponse to treatmentBlastic phasePrevious therapyMassive splenomegalyMyeloproliferative diseaseSystemic toxicityGranulocytic leukemiaSpleen sizeSymptomatic reliefCytosine arabinosidePatientsSplenomegalyInfusionTreatmentHypersplenismPainLeukemiaTherapyArabinosideTreatment of Refractory Splenomegaly in Myeloproliferative Disease by Splenic Artery Infusion
Canellos G, Sutliffe S, DeVita V, Lister T. Treatment of Refractory Splenomegaly in Myeloproliferative Disease by Splenic Artery Infusion. Blood 1979, 53: 1014-1017. DOI: 10.1182/blood.v53.5.1014.1014.Peer-Reviewed Original ResearchSplenic artery infusionArterial infusionBlastic phase of chronic granulocytic leukemiaRefractory to previous therapyPhase of chronic granulocytic leukemiaChronic granulocytic leukemiaResponse to treatmentBlastic phasePrevious therapyMassive splenomegalyMyeloproliferative diseaseSystemic toxicityGranulocytic leukemiaSpleen sizeSymptomatic reliefCytosine arabinosidePatientsSplenomegalyInfusionTreatmentHypersplenismPainLeukemiaTherapyArabinoside